Global Antibody Drug Conjugates Market Projected to Reach Around USD 4,670 Million By 2026

29-Aug-2020 | Facts and Factors

Findings from Facts and Factors has authored “Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer, Lymphoma, and Other Types of Cancer):  Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2026” States that the global Antibody Drug Conjugates market in 2019 was approximately USD 2,000 Million. The market is expected to grow above a CAGR of 12.9% and is anticipated to reach over USD 4,670 Million by 2026.

Antibody drug conjugates are usually used to treat cancer and therefore are better and safer than most other cancer therapies. The increased incidence of cancer growth combined with the development of the geriatric population is likely to have an impact on the Antibody-Drug Conjugates market. Moreover, major innovative progressions are likewise adding to drive the development. As estimated by the World Health Organization (WHO), the number of individuals aged 65 years or more is projected to reach 16 % of the total population by 2050, compared to 7% in 2000. Maturing has become a significant hazard factor for various illnesses including cancer and others. Consequently, the developing geriatric populace is projected to drive the development of the market over the figure time frame.

Browse the full “Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer, Lymphoma, and Other Types of Cancer):  Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2026" https://www.fnfresearch.com/antibody-drug-conjugates-market-by-drugs-adcetris-and

Impressive financial investments involving technologies and their small distribution are likely to boost the growth of the market. In addition, the increasing use of Antibody Drug Conjugates in different sections of end-users across developing countries is a component that stimulates market growth. However, high capital cost and rigid regulatory regulations are the key factors restricting the growth of the sector.

The Antibody Drug Conjugates industry has been segmented on the basis of drugs, application, mechanism of action, and region. The drugs segment is divided into adcetris and kadcyla. The Adcetris division had the largest market share in 2019, with the fastest increase expected in the near future. ADCs have been attracting a lot of interest from both small and major pharmaceutical firms because of effective marketing and advanced technologies.

Further, the mechanism of action segment is classified as HER2 antibodies and CD30 antibodies. Additionally, the application segment is classified as lymphoma, breast cancer, and others. Breast cancer was the largest share in 2019 and is likely to experience greater growth over the coming years due to various factors such as Kadcyla availability and high incidence of breast cancer.

The world market is categorized as Latin America, APAC, North America, Europe, and the MEA regions. North America is projected to control the global market quickly due to the increasing proliferation of technologically innovative technologies in the countries of the region. This rise in demand is attributed due to increasing individual awareness regarding the usage of advanced healthcare in the region. North America is a very well-established region in terms of medical knowledge and the use of ADCs and makes up most of the established market. However, Asia Pacific is likely to expand at a high CAGR during the forecast time due to the Covid-19 outbreak in Wuhan Province in China and further widespread into neighboring countries.

Report Scope

The major players operating in the market are Synthon Holding B.V., Seattle Genetics Inc., Sanofi S.A., Progenics Pharmaceuticals Inc., Pfizer, Inc., Immunomedics, Inc., Immunogen Inc., Genentech Inc., Celldex Therapeutics Inc., and Bayer Healthcare Pharmaceuticals among others. Major operating players in the Antibody Drug Conjugates market concentrate on manufacturing more advanced, reliable, and cost-effective masks to lead to the growth of revenues in the industry.

This report segments the Antibody Drug Conjugates market as follows:

Global Antibody Drug Conjugates Market: Drugs Segment Analysis

• Adcetris
• Kadcyla

Global Antibody Drug Conjugates Market: Mechanism of Action Segment Analysis

• CD30 Antibodies
• HER2 Antibodies

 Global Antibody Drug Conjugates Market: Application Segment Analysis

• Breast Cancer
• Lymphoma

Global  Antibody Drug Conjugates Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com